EDGE Edge Therapeutics

PDS Biotechnology Announces Participation in Noble Capital Markets Virtual Road Show Series

PDS Biotechnology Announces Participation in Noble Capital Markets Virtual Road Show Series
EN
01/10/2020

Underlying

EDGEEdge Therapeutics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Edge Therapeutics

 PRESS RELEASE
Free
EDGE Edge Therapeuti...

PDS Biotechnology Announces Participation in Noble Capital Markets Vir...

PDS Biotechnology Announces Participation in Noble Capital Markets Virtual Road Show Series

October 1, 2020 1 EN
 PRESS RELEASE
Free
EDGE Edge Therapeuti...

PDS Biotechnology to Present Results from its Phase 1 Trial of PDS0101...

PDS Biotechnology to Present Results from its Phase 1 Trial of PDS0101 and the Phase 2 Clinical Strategy in Patients with Advanced HPV-Associated Malignancies FLORHAM PARK, N.J., Sept. 28, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that its Chief Medical Officer, Lauren V. Wood, M.D. will present key data from the company’s previously ...

September 28, 2020 1 EN
 PRESS RELEASE
Free
EDGE Edge Therapeuti...

PDS Biotechnology to Participate in Upcoming Healthcare Investor Confe...

PDS Biotechnology to Participate in Upcoming Healthcare Investor Conferences FLORHAM PARK, N.J., Sept. 08, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (“PDS Biotech” or the “Company”) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced that Frank Bedu-Addo, CEO of PDS Biotech, will present virtually at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 16th and the Oppenheimer Fall Healthcar...

September 8, 2020 1 EN
 PRESS RELEASE
Free
EDGE Edge Therapeuti...

PDS Biotechnology Announces Participation in Noble Capital Markets C-S...

PDS Biotechnology Announces Participation in Noble Capital Markets C-Suite Interview Series FLORHAM PARK, N.J., Aug. 31, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced its participation in Noble Capital Markets’ C-Suite Interview Series, presented by Channelchek.  The interview was led by Noble Capital Markets Biotechnology Analyst Ahu Demir, Ph.D.  Joining Ahu was Frank...

August 31, 2020 1 EN
 PRESS RELEASE
Free
EDGE Edge Therapeuti...

PDS Biotechnology Corporation Announces Closing of Approx. $19 Million...

PDS Biotechnology Corporation Announces Closing of Approx. $19 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares FLORHAM PARK, N.J., Aug. 13, 2020 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotechnology" or the "Company"), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology, today announced the closing of its previously announced underwritten public offering of 6,900,000 shares of common s...

August 13, 2020 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch